Lactate Buildup Drives Vascular Aging via a Key Epigenetic Switch in Artery Cells
A newly identified lactate-CEBPB-CXCL12/p21 axis drives vascular smooth muscle cell senescence and inflammation, linking metabolic reprogramming to aortic aneurysm.
Summary
Researchers discovered that lactate accumulation in vascular smooth muscle cells (VSMCs) triggers a chain reaction that accelerates cellular aging and inflammation — two hallmarks of abdominal aortic aneurysm (AAA). Lactate chemically modifies histones (the protein spools around which DNA is wound) in a process called lactylation, which switches on a transcription factor called CEBPB. CEBPB then activates two downstream genes — CXCL12 and p21 — that promote VSMC senescence, fuel inflammatory signaling, and skew immune macrophages toward a pro-inflammatory state. Importantly, blocking lactate production or silencing these downstream genes reversed much of the damage. The findings, supported by human AAA tissue samples, nominate the lactate-CEBPB axis as a potential therapeutic target for slowing vascular aging and aneurysm progression.
Detailed Summary
Abdominal aortic aneurysm (AAA) is a life-threatening vascular condition in which the aortic wall progressively weakens, partly due to the dysfunction of vascular smooth muscle cells (VSMCs). Understanding what drives VSMC senescence and inflammation is critical for developing therapies that could slow aneurysm growth and reduce rupture risk — a problem that scales directly with aging populations.
This study focused on a relatively new concept in cellular biology: histone lactylation, a post-translational modification in which lactate — a byproduct of increased glycolysis — chemically tags histones and alters gene expression. Using an angiotensin II (AngII)-induced VSMC injury model alongside human AAA tissue samples, the researchers mapped a pathway from lactate accumulation to vascular pathology.
Key results showed that AngII treatment elevated lactate production and histone H3 lysine 18 lactylation (H3K18la) in VSMCs. This epigenetic mark enriched at the CEBPB gene promoter, increasing CEBPB expression. CEBPB in turn directly bound the promoters of CXCL12 and p21, transcriptionally activating both. Elevated p21 promoted VSMC senescence — confirmed by SA-β-gal staining, elevated P16, and increased senescence-associated secretory phenotype (SASP) factors including IL-6 and MMP2. Elevated CXCL12 amplified inflammatory cytokine secretion and tipped macrophage polarization toward the pro-inflammatory M1 phenotype while suppressing anti-inflammatory M2 polarization. Blocking glycolysis with 2-DG or silencing p21/CXCL12 reversed these effects.
For longevity medicine, this work matters because it mechanistically links metabolic dysfunction (excess lactate) to epigenetic reprogramming and vascular cell senescence — a triangle at the heart of cardiovascular aging. The lactate-CEBPB-CXCL12/p21 axis is now a candidate target for anti-senescence and anti-inflammatory interventions in AAA and potentially broader vascular aging contexts.
Caveats are significant: all mechanistic experiments are in vitro, and the human tissue data are correlational. In vivo validation in animal aneurysm models is explicitly acknowledged as a necessary next step before any clinical translation can be considered.
Key Findings
- Lactate accumulation in VSMCs drives histone H3K18 lactylation, epigenetically upregulating the transcription factor CEBPB.
- CEBPB directly activates CXCL12 and p21 promoters, linking metabolic stress to VSMC senescence and inflammation.
- Silencing p21 reversed AngII-induced VSMC senescence, ROS production, and SASP factor secretion in vitro.
- CXCL12 knockdown reduced pro-inflammatory M1 macrophage polarization and restored anti-inflammatory M2 balance.
- Both H3K18la and CEBPB/CXCL12/p21 expression were elevated in human AAA tissue, supporting clinical relevance.
Methodology
The study used an angiotensin II-induced in vitro VSMC injury model, measuring lactate production, oxygen consumption rate, and extracellular acidification rate. Senescence was confirmed by SA-β-gal staining, immunofluorescence, and SASP factor quantification via ELISA; epigenetic interactions were mapped using chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. Findings were corroborated with mRNA and protein data from human AAA patient tissues.
Study Limitations
All mechanistic findings are derived from in vitro cell models; no in vivo animal aneurysm experiments were performed, limiting causal conclusions about AAA progression. Human AAA tissue data are observational and cannot establish directionality of the identified pathway. This summary is based on the abstract only, as the full paper was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: